CN104745689A - Primers, probe and kit used for detecting bordetella pertussis - Google Patents
Primers, probe and kit used for detecting bordetella pertussis Download PDFInfo
- Publication number
- CN104745689A CN104745689A CN201510050933.6A CN201510050933A CN104745689A CN 104745689 A CN104745689 A CN 104745689A CN 201510050933 A CN201510050933 A CN 201510050933A CN 104745689 A CN104745689 A CN 104745689A
- Authority
- CN
- China
- Prior art keywords
- bordetella pertussis
- probe
- test kit
- working standard
- quality control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses primers, probe and kit used for detecting bordetella pertussis, belonging to the technical field of biology. The primers and probe comprise a forward primer, a reverse primer and a probe, which are used for detecting bordetella pertussis. The kit comprises the primers and the probe. The primers, the probe and the kit have the characteristic of high sensitivity, the detection speed is high and the whole detection process only takes 2-3 hours.
Description
Technical field
The present invention relates to biological technical field, particularly a kind of primer, probe and test kit for detecting bordetella pertussis.
Background technology
Bordetella pertussis (Bordetella pertussis) is a kind of obligate aerobic Grain-negative dialister bacterium, belongs to bordetella bacillus, and without gemma, atrichia, new isolated strains is smooth type, has pod membrane and virulence.Unique host of bordetella pertussis is the mankind, the Whooping cough that bordetella pertussis mainly causes, and is a kind of acute respiratory disease, and infectivity is strong, and the general susceptible of crowd is wherein especially common with infant, is one of Infectious Diseases of serious threat human health.Be apt to occur in infant and age children less than normal, clinical manifestation is paroxysmal spasmodic cough, with inspiratory coda and vomiting, and the usual continued for several weeks of the course of disease, the easy Complicating Pneumonia In Patients of young infant, encephalopathic, epilepsy, thus need be in hospital or cause death.
In the immunological detection method of bordetella pertussis, generally get suspected patient acute phase and decubation 2 parts of serum specimens detect, this makes sample time longer, be unfavorable for the quick diagnosis of bordetella pertussis, meanwhile, immunology detection specificity is not high, accurately can not detect bordetella pertussis.
Summary of the invention
In order to solve in prior art the slow and problem that specificity is not high of the detection speed detecting bordetella pertussis, embodiments provide a kind of primer, probe and test kit for detecting bordetella pertussis.Described technical scheme is as follows:
On the one hand, embodiments provide a kind of primer for detecting bordetella pertussis and probe, described primer and probe comprise: for detect bordetella pertussis forward primer, for detecting the reverse primer of bordetella pertussis and the probe for detecting bordetella pertussis, wherein
The described forward primer for detecting bordetella pertussis is as shown in SEQ ID NO.1 in sequence table;
The described reverse primer for detecting bordetella pertussis is as shown in SEQ ID NO.2 in sequence table;
The described probe for detecting bordetella pertussis is as shown in SEQ ID NO.3 in sequence table;
5 ' end of described probe is connected with fluorophor FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, and 3 ' end of described probe is connected with quenching group TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL.
On the other hand, embodiments provide a kind of test kit for detecting bordetella pertussis, described test kit comprises above-mentioned primer and probe.
Particularly, described test kit also comprises: nucleic acid releasing agent, PCR reaction solution, critical positive quality control product, positive quality control product, negative quality control product and working standard.
Particularly, described working standard comprises: working standard 1, working standard 2, working standard 3 and working standard 4, wherein,
Described working standard 1 is for containing 1.0 × 10
7the bordetella pertussis gene fragment of copy/mL;
Described working standard 2 is for containing 1.0 × 10
6the bordetella pertussis gene fragment of copy/mL;
Described working standard 3 is for containing 1.0 × 10
5the bordetella pertussis gene fragment of copy/mL;
Described working standard 4 is for containing 1.0 × 10
4the bordetella pertussis gene fragment of copy/mL.
Particularly, described positive quality control product is 1.0 × 10
6the gene fragment of the bordetella pertussis of copy/mL.
Particularly, the final concentration of described forward primer and described reverse primer is 0.05-0.9 μM, and the final concentration of described probe is 0.05-0.9 μM.
Particularly, each component of described PCR reaction solution comprises in pcr amplification reaction system: dNTPs, 10 × PCR damping fluid and final concentration that the Taq enzyme that final concentration is 0.01U/ μ L ~ 0.05U/ μ L, final concentration are 0.2 ~ 0.6mM are the solution containing Mg ion of 1.5 ~ 5.0mM.
Particularly, the Triton X-100 that described nucleic acid releasing agent comprises sterilized water, final concentration is 0.03-0.3%, final concentration to be Nonyl pheno (40) ether of 0.04-0.4% and pH value be 8.3 final concentration be three (methylol) aminomethane of 0.01-0.1M.
Particularly, described critical positive quality control product is 1.0 × 10
4the gene fragment of the bordetella pertussis of copy/mL.
Particularly, the final concentration of described primer is 0.05-0.9 μM, and the final concentration of described probe is 0.05-0.9 μM.
Particularly, described negative quality control product is the physiological saline of concentration 0.8%.
The beneficial effect that the technical scheme that the embodiment of the present invention provides is brought is: primer and probe for detecting bordetella pertussis that the embodiment of the present invention provides, there is highly sensitive characteristic, the test kit for detecting bordetella pertussis that the embodiment of the present invention is provided, there is highly sensitive characteristic, instrument is adopted to collect fluorescent signal, avoid the subjectivity that naked eyes judge, its detected result is reliable, this test kit of object fragment that only there is single copy improves the sensitivity of detection, even if also can effectively detect; Detection speed is fast, and whole testing process only needs 2 ~ 3 hours altogether.
Accompanying drawing explanation
In order to be illustrated more clearly in the technical scheme in the embodiment of the present invention, below the accompanying drawing used required in describing embodiment is briefly described, apparently, accompanying drawing in the following describes is only some embodiments of the present invention, for those of ordinary skill in the art, under the prerequisite not paying creative work, other accompanying drawing can also be obtained according to these accompanying drawings.
Fig. 1 is the amplified fluorescence graphic representation that the embodiment of the present invention 2 provides;
Fig. 2 is the amplified fluorescence graphic representation that the embodiment of the present invention 3 provides;
Fig. 3 is the amplified fluorescence graphic representation that the embodiment of the present invention 4 provides;
Fig. 4 is the amplified fluorescence graphic representation of the typical curve that the embodiment of the present invention 5 provides;
Fig. 5 is the amplified fluorescence graphic representation that the embodiment of the present invention 5 provides;
Fig. 6 is the canonical plotting obtained by Fig. 4 that the embodiment of the present invention 5 provides, and Fig. 6 X-coordinate is LogStarting Quantity copy number, and ordinate zou is Threshold Cycle.
In figure: Cycles is cycle number, RFU is fluorescent value, and Log Starting Quantity copy number is the logarithmic value of bordetella pertussis initial concentration, and Ct (Threshold Cycle) value is cycle number; Sample 7 in sample 6,7a-embodiment 2 in sample 5,6a-embodiment 2 in sample 4,5a-embodiment 2 in sample Isosorbide-5-Nitrae a-embodiment 2 in 1a-embodiment 2.
Embodiment
For making the object, technical solutions and advantages of the present invention clearly, below in conjunction with accompanying drawing, embodiment of the present invention is described further in detail.In following examples, agents useful for same and probe are mainly purchased from precious biotechnology (Dalian) company limited.
The primer that embodiment 1. 1 kinds detects for bordetella pertussis nucleic acid quantification and fluorescent probe
Embodiments provide a kind of primer for detecting bordetella pertussis and probe, primer and probe comprise: for detect bordetella pertussis forward primer, for detecting the reverse primer of bordetella pertussis and the probe for detecting bordetella pertussis, wherein,
For detecting the forward primer of bordetella pertussis as shown in SEQ ID NO.1 in sequence table;
For detecting the reverse primer of bordetella pertussis as shown in SEQ ID NO.2 in sequence table;
For detecting the probe of bordetella pertussis as shown in SEQ ID NO.3 in sequence table;
5 ' end of probe is connected with fluorophor FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, and 3 ' end of probe is connected with quenching group TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL.In embodiments of the present invention, the fluorescent reporter group of probe is the excitation wavelength of FAM, FAM is 485nm, and reception wavelength is 527nm; Quenching group is Eclipse.Way of purification can be selected from: HAP, PAGE and HPLC way of purification, and primer and probe are as following table particularly:
Table 1. bordetella pertussis primer and probe
In table 1: F:forward, forward; Bordetella pertussis-F represents the forward primer of bordetella pertussis.R:reverse, oppositely; Bordetella pertussis-R represents the reverse primer of bordetella pertussis.P:probe, fluorescent probe (probe); Bordetella pertussis-P represents bordetella pertussis fluorescent probe, and fluorescent probe can be TaqMan fluorescent probe, TaqMan-MGB fluorescent probe, LNA fluorescent probe or MGB fluorescent probe.The primer of the design of table 1 and probe all entrust precious biotechnology (Dalian) company limited to synthesize.
The primer that the embodiment of the present invention provides and probe have highly sensitive characteristic, and accurately can detect the content of the bordetella pertussis in testing sample.
Embodiment 2. 1 kinds is for detecting the test kit of bordetella pertussis
Embodiments provide a kind of test kit for detecting bordetella pertussis nucleic acid quantification, this test kit comprises the primer and probe that the embodiment of the present invention 1 provides, and this test kit also comprises: nucleic acid releasing agent, PCR reaction solution, critical positive quality control product, positive quality control product, negative quality control product and working standard.
Particularly, each component of PCR reaction solution comprises in pcr amplification reaction system: dNTPs, 10 × PCR damping fluid and final concentration that the Taq enzyme that final concentration is 0.01U/ μ L ~ 0.05U/ μ L, final concentration are 0.2 ~ 0.6mM are the solution containing Mg ion of 1.5 ~ 5.0mM.In the present embodiment, the proportioning of each component concentration of PCR reaction solution is: dNTPs2 μ L, 10 × PCR Buffer 5 μ L and concentration that the Taq enzyme 0.3 μ L that concentration is 5U/ μ L, concentration are 10mmol/L are the MgCl of 25mmol/L
2solution 5 μ L.
Particularly, the final concentration of forward primer and reverse primer is 0.05-0.9 μM (forward primer and reverse primer are 0.05-0.9 μM), and the final concentration of probe is 0.05-0.9 μM.In the present embodiment, concentration is that 10 μm of ol/L primers add 2.5 μ L, and concentration is that 10 μm of ol/L probes add 2.5 μ L.
In actual application, primer and probe together can be added in PCR reaction solution and form reaction system, then to add sterilized water to volume be 49.5 μ L.
Particularly, the final concentration of nucleic acid releasing agent: Triton-X100 (Triton X-100) is 0.03%, the final concentration of NP-40 (Nonyl pheno (40) ether) be 0.04% and pH value be 8.3 final concentration be the Tris-HCL (Tutofusin tris) of 0.01M, solvent is sterilized water.
Particularly, negative quality control product to be concentration be 0.8% physiological saline.Weigh 0.008g solid sodium chloride and be dissolved in 1ml distilled water, mixing, directly draw 0.5 μ L and make negative quality control product.
Particularly, positive quality control product comprises containing concentration is 1.0 × 10
6the solution of the bordetella pertussis gene fragment of copy/mL.Get containing bordetella pertussis liquid, bacterial strain is by China typical culture collection center (China Center forType CultureCollection, CCTCC) provide, after cultivating, get and add after isopyknic nucleic acid releasing agent fully mixes containing bordetella pertussis liquid 100 μ L, more centrifugal 5min, 12000rpm, get supernatant liquor spectrophotometric measurement A260 quantitative, be then diluted to 1.0 × 10
6copy/mL, namely can be used as positive quality control product template.
Particularly, critical positive quality control product comprises containing concentration is 1.0 × 10
4the DNA fragmentation solution of the bordetella pertussis gene of copy/mL.Get containing bordetella pertussis liquid, bacterial strain is provided by China typical culture collection center (CCTCC), after cultivating, get and add isopyknic nucleic acid releasing agent containing bordetella pertussis liquid 100 μ L, after abundant mixing, more centrifugal 5min, 12000rpm, get supernatant liquor spectrophotometric measurement A260 quantitative, be then diluted to 1.0 × 10
4copy/mL, namely can be used as critical positive quality control product.
Particularly, working standard comprises: working standard 1, working standard 2, working standard 3 and working standard 4, and wherein, working standard 1 is 1.0 × 10
7the non-infectious DNA fragmentation of the bordetella pertussis gene of copy/mL;
Working standard 2 is 1.0 × 10
6the non-infectious DNA fragmentation of the bordetella pertussis gene of copy/mL;
Working standard 3 is 1.0 × 10
5the non-infectious DNA fragmentation of the bordetella pertussis gene of copy/mL;
Working standard 4 is 1.0 × 10
4the non-infectious DNA fragmentation of the bordetella pertussis gene of copy/mL.
Working standard is the pUC57-T recombinant plasmid of the nucleotide fragments of high conservative gene containing bordetella pertussis, alkaline lysis method of extracting DNA is used after this recombinant plasmid transformed bacillus coli DH 5 alpha propagation, through DNA Purification Kit, with spectrophotometric measurement A260 quantitative, be then diluted to 1.0 × 10 according to formula scales
8copy/mL, in-20 DEG C of preservations.Stock concentration is 1.0 × 10
8copy/mL, uses front stroke-physiological saline solution or 0.1mol/L PBS damping fluid (pH value is 7.6) to carry out the serial dilution of 10 times of gradients.Working concentration is followed successively by 1.0 × 10
7copy/mL, 1.0 × 106 copies/mL, 1.0 × 10
5copy/mL and 1.0 × 10
4copy/mL, before using, through the centrifugal 30s of 10,000rmp, gets supernatant liquor as working standard.The Kit components that the present embodiment provides is as follows:
Table 2. test kit configuration (24 person-portions/box):
This test kit can store-10 DEG C ± 5 DEG C lucifuges, avoid multigelation, the quantitative real time PCR Instrument that this test kit is suitable for comprises: Roche LightCycler480, ABI7500, ABI7300, Bio-Rad iQ5TM, Stratagene Mx3000P, Stratagene Mx3005P and Da An 7000 etc.
The test kit provided by the embodiment of the present invention 2 detects bordetella pertussis on Bio-Rad iQ5TM quantitative real time PCR Instrument, and concrete grammar is as follows:
(1) collected specimens: sample all derives from Wuhan Infectious Diseases Hospital, wherein 5 is positive known after testing, 3 is negative sample known after testing, sample can be sputum or throat swab, in 5 known after testing positive, there are 3 samples to be sputum, all the other 2 is throat swab, and in 3 known after testing negative samples, have 1 sample to be sputum, all the other 2 is throat swab.
1. the pre-treatment of sputum: 1) get 0.5ml sputum sample product and add sample volume 1-3 4%NaOH solution doubly, liquefaction 15min, wherein the add-on of NaOH solution is depending on the viscosity of Sputum samples, and what viscosity was low adds 1-2 times, what viscosity was high adds 2-3 times of volume, is entirely standard to liquefy; 2) sucking-off 1ml post liquefaction sample is placed in 1.5ml centrifuge tube, and the centrifugal 5min of 15000r/min, removes supernatant.Add 800 μ L sterilizing TE damping fluids, fully shake mixing, the centrifugal 2min of 15000r/min, removes supernatant liquor again, and precipitation TE damping fluid repeated washing 2 times, centrifuge tube 4 DEG C saves backup.
2. Pharyngeal swab samples process: take out the sample gathered, put into and 1mL PBS damping fluid (commercial reagent is housed, pH value is 7.4) Glass tubing in, after abundant concussion shakes up, extract cotton swab with tweezers in Glass tubing edge, liquid rotating in Glass tubing is moved in centrifuge tube, 12, the centrifugal 5min of 000rpm, abandons supernatant, adds 500 μ l PBS damping fluids (pH value is 7.4), 12, the centrifugal 5min of 000rpm, abandons supernatant, then adds 500 μ l PBS damping fluids (pH value is 7.4), 12, the centrifugal 5min of 000rpm, abandons supernatant, and sample hose 4 DEG C saves backup.
Sample retention and transport: if sample is not tested immediately, should be stored in-20 DEG C, avoid multigelation.The long-distance transport of sample should adopt 0 DEG C of curling stone.
(2) sample preparation: get after testing sample and equivalent volumes DNA extraction liquid fully mixes, be the sample after process.
(3) application of sample: add each 0.5 μ L of the sample after process, negative quality control product, positive quality control product, critical positive quality control product and working standard respectively in the PCR reaction tubes that PCR reaction solution, primer and probe be housed, the volume ratio of PCR reaction solution and sample, negative quality control product, positive quality control product, critical positive quality control product or working standard after processing is 99:1, through the centrifugal 10s of 5,000rpm.
(4) pcr amplification: the reactive tank each reaction tubes being put into quantitative fluorescent PCR instrument, arranges mark fluorescent radical species, sample ID and type, definition sample well: negative quality control product selects NTC; The choosing of measuring samples, positive quality control product and critical positive quality control product select Unknown.
Pcr amplification is carried out by program below:
95 DEG C 3 minutes;
95 DEG C 10 seconds, 60 DEG C 1 minute (collection fluorescent signal), 40 circulations.
(5) judgement is analyzed:
Ct value be less than 28 for positive; Ct value be greater than 32 for negative; Ct value be more than or equal to 28 and be less than or equal to 32 for the critical positive.The amplification that the embodiment of the present invention provides is (Fig. 1 can judge sample result when Ct value is 32) as shown in Figure 1, and concrete detected result sees the following form 3.
The Ct value that the sample that table 3 provides for embodiment 2 is corresponding
| Sequence number | Ct value |
| 1 | 24.63 |
| 2 | N/A |
| 3 | N/A |
| 4 | 19.38 |
| 5 | 26.32 |
| 6 | 25.78 |
| 7 | 24.08 |
| 8 | N/A |
Wherein, sample Isosorbide-5-Nitrae, 5,6,7 in positive scope, is positive; N/A represents negative, sample 2,3,8 in negative range, is negative sample, result is consistent with known, the test kit specificity that the visible embodiment of the present invention 2 provides is 100%, and positive rate is 100%, for Fig. 1, marked by positive amplification in FIG, the arrangement rule in Fig. 2-Fig. 5 is see Fig. 1.
Embodiment 3. 1 kinds is for detecting the test kit of bordetella pertussis
Embodiments provide a kind of test kit detecting bordetella pertussis nucleic acid in sample, the composition in the test kit provided in the composition of this test kit and embodiment 2 is distinguished and is:
The proportioning of each component concentration of PCR reaction solution is: concentration is the Taq enzyme 0.1 μ L of 5U/ μ L, concentration is 10mmol/L dNTPs 1 μ L, 10 × PCR Buffer 5 μ L and concentration are the MgCl of 25mmol/L
2solution 3 μ L.
Concentration is that the forward primer of 10 μm of ol/L and reverse primer respectively add 0.25 μ L, and concentration is that 10 μm of ol/L probes add 0.25 μ L.
In actual application, primer and probe together can be added in PCR reaction solution, then to add sterilized water to volume be 10 μ L.
DNA extraction liquid comprise final concentration be 0.15% chloroform, final concentration be 0.25% Virahol and final concentration be the ethanol of 0.36%.
Test kit configuration (24 person-portions/box) that table 4. embodiment 3 provides:
Collected specimens: sample all derives from Wuhan Infectious Diseases Hospital, wherein 8 is positive known after testing, and 2 is negative sample known after testing.Other steps are see embodiment 2, and difference is:
Application of sample: add the sample after process, negative quality control product, positive quality control product and critical positive quality control product 40 μ L respectively in the PCR reaction tubes that 10 μ LPCR reaction solutions are housed, build pipe lid, the centrifugal 10s of 5,000rpm.
Operated according to the step in embodiment 2 by above-mentioned 10 samples, the amplification that the embodiment of the present invention provides as shown in Figure 2, obtains concrete detected result in table 5.
The Ct value that the sample that table 5 provides for embodiment 3 is corresponding
| Sequence number | Ct value |
| 1 | 23.75 |
| 2 | 28.25 |
| 3 | 22.59 |
| 4 | N/A |
| 5 | 22.38 |
| 6 | 25.86 |
| 7 | N/A |
| 8 | 21.45 |
| 9 | 19.64 |
| 10 | 31.24 |
In table 5, sample 1,3,5,6,8 and 9, in positive scope, is positive; Sample 2 and 10, in critical positive scope, is critical positive, positive totally 8 and conform to known detected result; Sample 4 and 7, in negative range, is negative sample, conforms to known detected result, and the test kit specificity that the visible embodiment of the present invention 3 provides is 100%, and positive rate is 100%.
Embodiment 4. 1 kinds is for detecting the test kit of bordetella pertussis
Embodiments provide a kind of test kit detecting bordetella pertussis nucleic acid in sample, the composition in the test kit provided in the composition of this test kit and embodiment 2 is distinguished and is:
The proportioning of each component concentration of PCR reaction solution is: concentration is the Taq enzyme 0.5 μ L of 5U/ μ L, concentration is 10mmol/L dNTPs 3 μ L, 10 × PCR Buffer 5 μ L and concentration are the MgCl of 25mmol/L
2solution 10 μ L.
Concentration is that the forward primer of 10 μm of ol/L and reverse primer respectively add 4.5 μ L, and concentration is that 10 μm of ol/L probes add 4.5 μ L.
In actual application, primer and probe together can be added in PCR reaction solution, then to add sterilized water to volume be 45 μ L.
DNA extraction liquid comprise final concentration be 0.3% chloroform, final concentration be 0.4% Virahol and final concentration be the ethanol of 0.6%.
The Reagent evaluation provided in all the other reagent and embodiment 2 with.
Collected specimens: sample all derives from Wuhan Infectious Diseases Hospital, wherein 6 is positive known after testing, and 2 is negative sample known after testing.Other steps are see embodiment 2, and difference is:
Application of sample: add each 5 μ L of the sample after process, negative quality control product, positive quality control product and critical positive quality control product respectively in the PCR reaction tubes that 10 μ L PCR reaction solutions are housed, the volume ratio of PCR reaction solution and sample, negative quality control product, positive quality control product or critical positive quality control product after processing is 9:1, build pipe lid, the centrifugal 10s of 5,000rpm.
Operated according to the step in embodiment 2 by above-mentioned 10 samples, the amplification that the embodiment of the present invention provides as shown in Figure 3, obtains concrete detected result in table 6.
The Ct value that the sample that table 6 provides for embodiment 4 is corresponding
| Sequence number | Ct value |
| 1 | 31.57 |
| 2 | 25.18 |
| 3 | 26.84 |
| 4 | 30.45 |
| 5 | N/A |
| 6 | N/A |
| 7 | 31.25 |
| 8 | 23.53 |
In table 6, sample 2,3 and 8, in positive scope, is positive; Sample 1,4 and 7, in critical positive scope, is critical positive, positive totally 6 and conform to known detected result; Sample 5 and 6, in negative range, is negative sample, conforms to known detected result, and the test kit specificity that the visible embodiment of the present invention 4 provides is 100%, and positive rate is 100%.
Embodiment 5. 1 kinds is for detecting the test kit of bordetella pertussis
When the test kit utilizing the embodiment of the present invention 4 to provide carries out detection by quantitative, need drawing standard curve, except 8 example reaction pipes, separately get 3 reaction tubess and be respectively negative quality control product, positive quality control product and critical positive quality control product, also have 4 reaction tubess, correspondence adds the working standard 5 μ L of different concns gradient in test kit, according to the method preparation PCR reaction system of embodiment 4, the centrifugal 10s of 5000rpm, then puts into instrument sample groove and carries out pcr amplification.Working standard selects Standard.For Standard, need to input 1.0 × 10 respectively in Quantity hurdle
7copy/ml, 1.0 × 10
6copy/ml, 1.0 × 10
5copy/ml, 1.0 × 10
4copy/ml and 1.0 × 10
3copy/ml.
Adopt and use instrument Bio-Rad iQ5TM to detect.
Reference results:
If a. not S-type or Ct value > 32 of amplification curve, judge that sample bordetella pertussis DNA content is less than Monitoring lower-cut;
If b. not obvious or 28≤Ct value≤32 of amplification curve S type, then sample bordetella pertussis DNA content is in critical positive scope;
If the c. S-type and Ct value ﹤ 28 of amplification curve, then carry out quantitatively by the following method: if the C of sample (" C " represents sample concentration or content) < 5.0000E+01, then bordetella pertussis DNA total content < 50 gene copy of this sample; If the 5.0000E+01≤C of sample≤5.0000E+07, then the bordetella pertussis DNA total content of this sample equals C gene copy; If the C > 5.0000E+07 of sample, then the bordetella pertussis DNA total content > 5.0000E+07 gene copy of this sample, detect in diluted sample to linearity range, concrete detected result is in table 7 again;
The initial concentration that table 7 is Ct value and correspondence thereof
| Working standard | Ct value | C (initial concentration) |
| 1.0e+007 | 18.65 | 1.0e+007 |
| 1.0e+006 | 21.98 | 1.0e+006 |
| 1.0e+005 | 25.31 | 1.0e+005 |
| 1.0e+004 | 28.64 | 1.0e+004 |
| Slope | -3.33 | - |
| Intercept | 41.96 | - |
| R 2 | 1 | - |
| Standard equation | y＝-3.33x+41.96 | - |
The amplification curve of the sample that the embodiment of the present invention 5 provides as shown in Figure 5, the working standard that the embodiment of the present invention 5 provides detects together with 8 samples, according to the Ct value obtained after amplification, looks into the typical curve of Fig. 6, again through converting, finally obtain the starting point concentration of 8 samples as following table.
| Sequence number | Ct value | C (initial concentration) |
| Positive quality control product | 19.34 | 6.206e+006 |
| Critical positive quality control product | 29.64 | 5.008e+003 |
| Negative quality control product | N/A | - |
| 1 | 26.01 | 6.163e+004 |
| 2 | 25.43 | 9.024e+004 |
| 3 | 34.24 | 2.080e+002 |
| 4 | 22.42 | 7.377e+005 |
| 5 | N/A | - |
| 6 | N/A | - |
| 7 | N/A | - |
| 8 | 26.03 | 6.078e+004 |
Amplification curve is all in smooth " S " type, and typical curve is straight line, and Ct value is between 14-28, and the Ct value difference of each concentration gradient is about 3.33.Monitoring lower-cut can be accurate to 5.000e+002, and as can be seen here, this test kit has highly sensitive.
Embodiments provide a kind of primer and probe of bordetella pertussis qualitative and quantitative detection, the real-time TaqMan quantitative fluorescent PCR that the embodiment of the present invention provides, its primer and fluorescent probe have high specific and highly sensitive, its test kit can accurate quantification, and its detection method can rapid detection bordetella pertussis.Real-time TaqMan quantitative fluorescent PCR detects target gene with stopped pipe pattern by sequence-specific TaqMan fluorescent probe while amplification, thus can increase the possibility of specificity and reduction crossed contamination.In addition, the embodiment of the present invention does not need further downstream analysis, has saved the time of gel electrophoresis observations, and whole testing process only needs 2 ~ 3 hours altogether.In real-time TaqMan quantitative fluorescent PCR, each circulation of PCR primer accumulation is monitored in real time and is analyzed, and analyzes the cycle number (Ct value) reaching fluorescence threshold and just can directly report out DNA starting copy number.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. for detecting primer and the probe of bordetella pertussis, it is characterized in that, described primer and probe comprise: for detect bordetella pertussis forward primer, for detecting the reverse primer of bordetella pertussis and the probe for detecting bordetella pertussis, wherein,
The described forward primer for detecting bordetella pertussis is as shown in SEQ ID NO.1 in sequence table;
The described reverse primer for detecting bordetella pertussis is as shown in SEQ ID NO.2 in sequence table;
The described probe for detecting bordetella pertussis is as shown in SEQ ID NO.3 in sequence table;
5 ' end of described probe is connected with fluorophor FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, and 3 ' end of described probe is connected with quenching group TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL.
2. for detecting a test kit for bordetella pertussis, it is characterized in that, described test kit comprises primer as claimed in claim 1 and probe.
3. test kit according to claim 2, is characterized in that, described test kit also comprises: nucleic acid releasing agent, PCR reaction solution, critical positive quality control product, positive quality control product, negative quality control product and working standard.
4. test kit according to claim 3, is characterized in that, described working standard comprises: working standard 1, working standard 2, working standard 3 and working standard 4, wherein,
Described working standard 1 is 1 × 10
7the gene fragment of the described bordetella pertussis of copy/mL;
Described working standard 2 is 1 × 10
6the gene fragment of the described bordetella pertussis of copy/mL;
Described working standard 3 is 1 × 10
5the gene fragment of the described bordetella pertussis of copy/mL;
Described working standard 4 is 1 × 10
4the gene fragment of the described bordetella pertussis of copy/mL.
5. test kit according to claim 3, is characterized in that, described positive quality control product is 1.0 × 10
6the gene fragment of the described bordetella pertussis of copy/mL.
6. test kit according to claim 3, is characterized in that, the final concentration of described forward primer and described reverse primer is 0.05-0.9 μM, and the final concentration of described probe is 0.05-0.9 μM.
7. test kit according to claim 3, it is characterized in that, each component of described PCR reaction solution comprises in pcr amplification reaction system: dNTPs, 10 × PCR damping fluid and final concentration that the Taq enzyme that final concentration is 0.01U/ μ L ~ 0.05U/ μ L, final concentration are 0.2 ~ 0.6mM are the solution containing Mg ion of 1.5 ~ 5.0mM.
8. test kit according to claim 3, it is characterized in that, described nucleic acid releasing agent comprises sterilized water, Nonyl pheno (40) ether that Triton X-100 that final concentration is 0.03-0.3%, final concentration are 0.04-0.4% and pH value be 8.3 final concentration be three (methylol) aminomethane of 0.01-0.1M.
9. test kit according to claim 3, is characterized in that, described critical positive quality control product is 1.0 × 10
4the gene fragment of the described bordetella pertussis of copy/mL.
10. test kit according to claim 3, is characterized in that, described negative quality control product is the physiological saline of concentration 0.8%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510050933.6A CN104745689A (en) | 2015-01-30 | 2015-01-30 | Primers, probe and kit used for detecting bordetella pertussis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510050933.6A CN104745689A (en) | 2015-01-30 | 2015-01-30 | Primers, probe and kit used for detecting bordetella pertussis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104745689A true CN104745689A (en) | 2015-07-01 |
Family
ID=53585939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510050933.6A Pending CN104745689A (en) | 2015-01-30 | 2015-01-30 | Primers, probe and kit used for detecting bordetella pertussis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104745689A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107190072A (en) * | 2017-06-22 | 2017-09-22 | 深圳市泰尔迪恩生物信息科技有限公司 | Primer combination of probe, kit and application for detecting pertussis Bao Te Salmonellas |
| CN107338286A (en) * | 2017-06-05 | 2017-11-10 | 深圳市儿童医院 | Primer combination of probe, PCR reaction solutions, kit and its application |
| CN107828910A (en) * | 2017-11-21 | 2018-03-23 | 弗罗朗（江苏）生物科技有限公司 | A kind of kit and its application method of quick single-minded detection Bordetella pertussis |
| CN108486259A (en) * | 2017-03-03 | 2018-09-04 | 绍兴迅敏康生物科技有限公司 | One-step method detects the kit and detection method of pertussis nucleic acid |
| CN113718046A (en) * | 2021-09-23 | 2021-11-30 | 深圳市儿童医院 | Bordetella pertussis genome specificity multi-copy sequence, corresponding primer and probe and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104195135A (en) * | 2014-08-05 | 2014-12-10 | 武汉海帝客生物科技有限公司 | Primer, target nucleotide amplifying method and target nucleotide amplification detecting method |
| CN104198704A (en) * | 2014-09-02 | 2014-12-10 | 张明 | Pertussis diagnostic kit and preparation method thereof |
-
2015
- 2015-01-30 CN CN201510050933.6A patent/CN104745689A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104195135A (en) * | 2014-08-05 | 2014-12-10 | 武汉海帝客生物科技有限公司 | Primer, target nucleotide amplifying method and target nucleotide amplification detecting method |
| CN104198704A (en) * | 2014-09-02 | 2014-12-10 | 张明 | Pertussis diagnostic kit and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| LAINA K ET AL.: "Evaluation of real-time PCR for diagnosis of Bordetella pertussis infection", 《BMC INFECTIOUS DISEASES》 * |
| 王慧等: "实时荧光定量PCR快速检测百日咳鲍特菌方法学建立及评价", 《临床检验杂志》 * |
| 罗炜等: "百日咳鲍特菌BP283基因的实时荧光定量PCR检测方法的建立", 《山东医药》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108486259A (en) * | 2017-03-03 | 2018-09-04 | 绍兴迅敏康生物科技有限公司 | One-step method detects the kit and detection method of pertussis nucleic acid |
| CN107338286A (en) * | 2017-06-05 | 2017-11-10 | 深圳市儿童医院 | Primer combination of probe, PCR reaction solutions, kit and its application |
| CN107190072A (en) * | 2017-06-22 | 2017-09-22 | 深圳市泰尔迪恩生物信息科技有限公司 | Primer combination of probe, kit and application for detecting pertussis Bao Te Salmonellas |
| CN107828910A (en) * | 2017-11-21 | 2018-03-23 | 弗罗朗（江苏）生物科技有限公司 | A kind of kit and its application method of quick single-minded detection Bordetella pertussis |
| CN113718046A (en) * | 2021-09-23 | 2021-11-30 | 深圳市儿童医院 | Bordetella pertussis genome specificity multi-copy sequence, corresponding primer and probe and application thereof |
| CN113718046B (en) * | 2021-09-23 | 2022-05-17 | 深圳市儿童医院 | Bordetella pertussis genome specificity multi-copy sequence, corresponding primer and probe and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104745689A (en) | Primers, probe and kit used for detecting bordetella pertussis | |
| CN103275862A (en) | Fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR) kit for detecting influenza A virus subtype H7N9 | |
| CN101633964B (en) | RNA detection kit for influenza A H1N1 virus | |
| CN103045761A (en) | Kit and detection method for detecting pathogenic microorganisms of infectious eye disease | |
| CN101363063B (en) | Primer, probe, kit and method for detecting A, B and H5 subtype influenza virus by triple fluorescent quantitative RT-PCR | |
| CN104593486A (en) | Primer, probe and kit all used for detecting blood fluke | |
| CN102634605B (en) | Method for detecting egg drop syndrome viruses and kit for method | |
| CN101333568B (en) | Quantitative determination process for enterovirus in environment water body | |
| CN103014135B (en) | A kind of method identifying mycobacterium tuberculosis | |
| CN104593485A (en) | Primer, probe and kit all used for detecting pneumocystis | |
| CN104745722A (en) | Primers, probe and kit used for detecting varicella zoster viruses (VZVs) | |
| CN102337356B (en) | Swine getah virus reverse transcription-polymerase chain reaction (RT-PCR) detection kit and application thereof | |
| CN104745724A (en) | Primers, probe and kit used for detecting JC viruses (JCVs) | |
| CN107513583A (en) | Detect the absolute fluorescence quantification PCR primer and kit of the pestivirus of atypia pig | |
| CN106435007A (en) | Primer, probe, kit and method for detecting bacillus erysipelatos-suis by fluorescent quantitative PCR (Polymerase Chain Reaction) | |
| CN103773884B (en) | For detecting the primer sets of Chlamydia pneumoniae 98KDa MOMP gene and probe and application thereof | |
| CN104745690A (en) | Primers, probe and kit used for detecting Klebsiella pneumoniae carbapenemase (KPC) genes | |
| CN107460249A (en) | A kind of primer, probe and kit for being used to detect methicillin-resistant staphylococcus aureus drug resistant gene | |
| CN104745688A (en) | Primers, probe and kit used for detecting drug-resistant genes of methicillin-resistant staphylococcus aureus (MRSA) | |
| CN104004837B (en) | PCR (polymerase chain reaction) primer, primer group, probe and kit for detecting mycobacterium tuberculosis and detection method | |
| CN109913544B (en) | Real-time fluorescent quantitative PCR kit for auxiliary diagnosis of tuberculous pleurisy and application thereof | |
| CN104073571B (en) | H7N9 subtype avian influenza virus double fluorescent RT-PCR primer, probe and detection kit thereof and detection method | |
| CN102925568B (en) | Primer and probe for detecting acidovorax citrulli and detection method for acidovorax citrulli | |
| CN110157836B (en) | Primer, probe and method for detecting IBRV and BVDV | |
| CN105779656A (en) | Porcine torque teno sus virus type 2 loop-mediated isothermal amplification kit and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150701 |
|
| RJ01 | Rejection of invention patent application after publication |